August 08, 2019 – SCHLIEREN, (Zurich, Switzerland). Biognosys, a Swiss proteomics company, continues realizing its ambition to enable clinical researchers to directly measure and quantify thousands of proteins from patient tissues in clinical trials by offering its next-generation label-free proteomics technology. To accelerate this development, the company has raised new funds in Series G financing round.
Biognosys provides proteomics research services to innovative pharma and biotech firms. They use the company’s technology in their pre-clinical research, providing deep and precise protein expression profiling for the development of biomarkers and analysis of mode of action. As demand for the use of these services in the clinical phase is growing, the new financing round will help the company to further scale up its operations and start serving clients’ drug development projects in the clinical phases.
Dr. Oliver Rinner, Founder and CEO of Biognosys, says: “We are striving to provide the deepest and most precise proteomics data to our clients. We are very excited with the perspective to be pioneers in bringing discovery proteomics to clinical trials and provide our advanced data analysis services at a much larger scale.”
The financing round includes a new industrial investor, in addition to existing institutional and private shareholders. The funds will be invested into building a new GCP-certified facility in Switzerland, increasing current operational capacity as well as enhancing the company’s sales force, further expanding its commercial presence in the US (both East and West Coast), Europe, and Asia.
Lidia Novak, CFA
Chief Financial Officer
Mobile +41 (0) 79 710 74 15
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science research by making the most advanced proteomics tools available to researchers. The company offers a suite of products and services to decode the proteome and equip researchers from all fields with a deep view of protein expression in cells, tissues, or body fluids. Biognosys’ technology is based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach, for unprecedented quantification of large proteomes in a single experiment. More information at: www.biognosys.com
Please find the official PRESSEBOX press release here.
Access our knowledge base with relevant resources and guiding information.